We are live on ! Find out more
DFTX

Definium Therapeutics
DFTX

151 hedge funds and large institutions have $299M invested in Definium Therapeutics in 2024 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 39 increasing their positions, 24 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

282% more call options, than puts

Call options by funds: $14.4M | Put options by funds: $3.77M

63% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 27

63% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 24

12% more funds holding

Funds holding: 135 → 151 (+16)

9% less capital invested

Capital invested by funds: $327M → $299M (-$28.2M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

26.45% less ownership

Funds ownership: 84.24% → 57.79% (-26%)

Holders
151
Holders Change
+16
Holders Change %
+11.85%
% of All Funds
2.18%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
44
Increased
39
Reduced
24
Closed
27
Calls
$14.4M
Puts
$3.77M
Net Calls
+$10.6M
Net Calls Change
-$11.6M

Top Buyers

1
BlackRock
BlackRock
New York
+$40.1M
2
State Street
State Street
Massachusetts
+$14.7M
3
CC
Commodore Capital
New York
+$11.5M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$10.3M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$9.84M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$18.8M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$8.11M
3
SCM
Soleus Capital Management
Connecticut
-$7.05M
4
DTC
Deep Track Capital
Connecticut
-$4.92M
5
Millennium Management
Millennium Management
New York
-$3.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
SRCM
126
Signature Resources Capital Management
California
$382 – – –
LI
127
Louisbourg Investments
New Brunswick, Canada
$375 – – –
PMFA
128
Plante Moran Financial Advisors
Michigan
$260 – – –
ACM
129
Anfield Capital Management
California
$260 +$315 +36 New
TCM
130
TruNorth Capital Management
Michigan
$238 +$289 +33 New
CAM
131
Chesapeake Asset Management
New York
$237 – – –
AAP
132
Arax Advisory Partners
Colorado
$202 – – –
RF
133
Robbins Farley
New Hampshire
$202 – – –
CA
134
Continuum Advisory
Idaho
$144 – – –
ACA
135
American Capital Advisory
Idaho
$121 – – –
CP
136
Castleview Partners
Texas
$115 – – –
EWP
137
Elevation Wealth Partners
California
$109 +$131 +15 New
CA
138
CoreCap Advisors
Michigan
$108 – – –
SIC
139
SJS Investment Consulting
Ohio
$87 – – –
JWM
140
Janiczek Wealth Management
Colorado
$73 – – –
CB
141
CNB Bank
Pennsylvania
$72 – – –
M
142
MOTCO
Texas
$72 +$87 +10 New
BC
143
Belmont Capital
California
$43 – – –
GEA
144
Glen Eagle Advisors
New Jersey
$43 – – –
HCP
145
Hexagon Capital Partners
Arkansas
$29 – – –
RIL
146
Rothschild Investment LLC
Illinois
$22 – – –
CAS
147
Coppell Advisory Solutions
Texas
$7 +$9 +1 New
HNB
148
Huntington National Bank
Ohio
$1 – – –
GPP
149
Great Point Partners
Connecticut
– -$18.8M -2,000,000 Closed
SCM
150
Soleus Capital Management
Connecticut
– -$7.05M -750,237 Closed
4 5
6
7 8

DFTX Hedge Fund Activity: Q2 2024 in Review

151 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2024, worth a combined $299M — down 8.6% from $327M a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new DFTX positions and 27 closed out — a net gain of 17 holders — while 39 added to existing stakes and 24 trimmed.

The largest buyer was BlackRock, adding an estimated $40.1M. The largest seller was Great Point Partners, exiting entirely with an estimated $18.8M sold.

  • 151 institutional investors held Definium Therapeutics (DFTX) as of Q2 2024, up from 135 in Q1 2024.
  • Funds reported $299M of Definium Therapeutics stock for Q2 2024, down 8.6% quarter-over-quarter.
  • 44 funds opened new Definium Therapeutics positions in Q2 2024 and 27 closed out, a net change of +17 holders.
  • The largest Definium Therapeutics buyer in Q2 2024 was BlackRock, an estimated $40.1M added.
  • The largest Definium Therapeutics seller in Q2 2024 was Great Point Partners, an estimated $18.8M sold.

Based on aggregated 13F filings for Q2 2024.